- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06619509
Um estudo para testar o tratamento de longo prazo com Brigimadlin em pessoas com tumores sólidos que participaram de um estudo anterior com este medicamento
Um ensaio de fase II, de braço único, aberto e de segurança de longo prazo de Brigimadlin oral em pacientes com tumores sólidos
This study is open to adults with solid tumours who received at least 4 cycles of treatment with brigimadlin in a previous study. The goal of this study is to find out how well people with solid tumours tolerate long-term treatment with brigimadlin. Brigimadlin is a so-called MDM2 inhibitor that was being developed to treat cancer.
All participants take brigimadlin as tablets once every 3 weeks at the study site. At study visits, doctors check participants' health and take note of any unwanted effects. At some study visits, doctors also check the size of the tumour and whether it has spread to other parts of the body. Participants are in the study as long as they benefit from treatment and can tolerate it.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
-
Berlin, Alemanha, 13125
- Helios Klinikum Berlin-Buch
-
Tübingen, Alemanha, 72076
- Universitätsklinikum Tübingen
-
-
-
-
-
CABA, Argentina, C1120AAB
- Sanatorio Finochietto
-
-
-
-
New South Wales
-
Randwick, New South Wales, Austrália, 2031
- Prince of Wales Hospital-Randwick-66496
-
-
Queensland
-
Woolloongabba, Queensland, Austrália, 4102
- Princess Alexandra Hospital
-
-
-
-
-
Brussels, Bélgica, 1200
- Cliniques Universitaires Saint-Luc
-
Leuven, Bélgica, 3000
- UZ Leuven
-
-
-
-
Alberta
-
Calgary, Alberta, Canadá, T2N 5G2
- Arthur J. E. Child Comprehensive Cancer Centre
-
-
Ontario
-
Toronto, Ontario, Canadá, M5G 2M9
- Princess Margaret Cancer Centre
-
-
-
-
-
Guangzhou, China, 510060
- Sun Yat-Sen University Cancer Center
-
-
-
-
-
København Ø, Dinamarca, 2100
- Copenhagen University Hospital, Rigshospitalet
-
-
-
-
-
Aragon, Espanha, 50009
- Hospital Universitario Miguel Servet
-
Madrid, Espanha, 28040
- Fundación Jiménez Díaz
-
Madrid, Espanha, 28041
- Hospital Universitario 12 de Octubre
-
Madrid, Espanha, 28050
- Hospital Universitario HM Sanchinarro
-
Santiago de Compostela, Espanha, 15706
- Hospital Clínico de Santiago
-
-
-
-
California
-
Beverly Hills, California, Estados Unidos, 90212
- Precision NextGen Oncology
-
Santa Monica, California, Estados Unidos, 90403
- Sarcoma Oncology Center
-
-
Connecticut
-
New Haven, Connecticut, Estados Unidos, 06511
- Yale Cancer Center
-
-
Florida
-
Jacksonville, Florida, Estados Unidos, 32224
- Mayo Clinic Cancer Center
-
-
Missouri
-
St Louis, Missouri, Estados Unidos, 63108
- Washington University School of Medicine
-
-
Nebraska
-
Omaha, Nebraska, Estados Unidos, 68130
- Nebraska Cancer Specialists-Omaha-69066
-
-
New York
-
Lake Success, New York, Estados Unidos, 11042
- Northwell Health
-
-
Tennessee
-
Germantown, Tennessee, Estados Unidos, 38138
- West Cancer Center & Research Institute
-
Nashville, Tennessee, Estados Unidos, 37232
- Henry-Joyce Cancer Clinic
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- The University of Texas MD Anderson Cancer Center
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84106
- Utah Cancer Specialists Cancer Center
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98109
- Fred Hutchinson Cancer Research Center
-
-
Wisconsin
-
Madison, Wisconsin, Estados Unidos, 53792
- University of Wisconsin
-
-
-
-
-
Lyon, França, 69373
- CTR Leon Berard
-
Rennes, França, 35042
- CTR Eugène Marquis
-
-
-
-
-
Gyöngyös, Hungria, 3200
- Clinexpert Gyongyos
-
-
-
-
-
Tel Aviv, Israel, 6423906
- Sourasky Medical Center
-
-
-
-
-
Milan, Itália, 20133
- Fondazione IRCCS Istituto Nazionale dei Tumori
-
Padova, Itália, 35128
- Istituto Oncologico Veneto IRCCS
-
-
-
-
-
Fukuoka, Fukuoka, Japão, 812-8582
- Kyushu University Hospital
-
Fukuoka, Fukuoka, Japão, 811-1395
- National Hospital Organization Kyushu Cancer Center
-
Kanagawa, Yokohama, Japão, 241-8515
- Kanagawa Cancer Center
-
Miyagi, Sendai, Japão, 980-8574
- Tohoku University Hospital
-
Okayama, Okayama, Japão, 700-8558
- Okayama University Hospital
-
Osaka, Osaka, Japão, 541-8567
- Osaka International Cancer Institute
-
Tokyo, Chuo-ku, Japão, 104-0045
- National Cancer Center Hospital
-
-
-
-
-
Oslo, Noruega, N-0379
- Oslo Universitetssykehus HF, Radiumhospitalet
-
-
-
-
-
Warsaw, Polônia, 02-781
- Oncology Center-Maria Sklodowska-Curie Institute
-
-
-
-
-
Cambridge, Reino Unido, CB2 0QQ
- Addenbrooke's Hospital
-
London, Reino Unido, SW3 6JJ
- The Royal Marsden Hospital, Chelsea
-
London, Reino Unido, NW12PQ
- University College Hospital
-
-
-
-
-
Stockholm, Suécia, SE-171 76
- Karolinska Comprehensive Cancer Center
-
-
-
-
-
Taipei, Taiwan, 11217
- Taipei Veterans General Hospital
-
-
-
-
-
Olomouc, Tcheca, 77900
- University Hospital Olomouc
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion criteria:
- Patient is ongoing on brigimadlin treatment in any trial sponsored by Boehringer Ingelheim (hereafter referred to as the 'parent trial').
- Provision of signed and dated, written informed consent form (ICF) in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - Good Clinical Practice (ICH-GCP) and local legislation prior to any trial-specific procedures, sampling, or analyses.
- Women of childbearing potential (WOCBP) and men able to father a child must be ready and able to use 2 medically acceptable methods of birth control per ICH M3 (R2) that result in a low failure rate of <1% per year when used consistently and correctly beginning at Screening, during trial participation, and until 6 months and 12 days after the last dose for women and 102 days after the last dose for men. A list of contraception methods meeting these criteria and instructions on the duration of use is provided in the participant information.
- Participants must be willing and able to comply with the scheduled visits, treatment plan, lifestyle, laboratory tests, contraceptive guidelines, and other study procedures.
- Adequate organ function.
- Patient is eligible to receive continued treatment according to the clinical trial protocol of the parent trial they are currently participating in. Patients currently experiencing a dose delay in the parent trial due to adverse events are eligible if recovery from the adverse event takes place within the allowed time window in the parent trial.
Exclusion criteria:
- Any medical condition which in the opinion of the investigator should exclude the patient from receiving treatment with brigimadlin.
- Participants who must receive or intend to receive restricted medications or any drug considered likely to interfere with the safe conduct of the trial.
- Women who are pregnant, nursing, or who plan to become pregnant while in the trial. Female patients who do not agree to the interruption of breastfeeding from the start of study treatment until 6 months and 12 days after the last dose of study treatment.
- Patient has unacceptable toxicity on brigimadlin at the time of transition into this trial.
- Patient has an adverse event (AE) which has caused a dose delay and has not recovered within the allowed time window in the parent trial.
- Patient who has already required 2 dose reductions and would require a third dose reduction at trial entry, unless the investigator deems treatment continuation beneficial, and the third dose reduction is agreed in writing between the investigator and the sponsor.
Further exclusion criteria apply.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Brigimadlina
|
Brigimadlin
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
The primary endpoint will be the occurrence of treatment-emergent adverse events (AEs) according to CTCAE Version 5.0 during the entire treatment period
Prazo: up to 9 years.
|
CTCAE=Common Terminology Criteria for Adverse Events |
up to 9 years.
|
Colaboradores e Investigadores
Patrocinador
Publicações e links úteis
Links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 1403-0032
- 2024-514177-21-00 (Identificador de registro: CTIS)
- U1111-1305-3484 (Identificador de registro: WHO International Clinical Trials Registry Platform (ICTRP))
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Once the criteria in section 'time frame' are fulfilled, researchers can use the following link https:// www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.
Prazo de Compartilhamento de IPD
One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.
Critérios de acesso de compartilhamento IPD
For study documents -upon signing of a 'Document Sharing Agreement'. For study data -1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- SEIVA
- CSR
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .